002370 亚太药业
已收盘 01-08 15:00:00
资讯
新帖
简况
亚太药业最新公告：公司收到浙江省高级人民法院下发的《民事裁定书》
证券之星 · 01-08 21:09
亚太药业最新公告：公司收到浙江省高级人民法院下发的《民事裁定书》
【抗流感概念持续走高 太龙药业等十余股涨停】抗流感概念午后涨势持续扩大，太龙药业、以岭药业午后双双涨停，另外罗欣药业、华北制药、亚太药业、金石亚药等十余只成分股涨停。
金融界 · 01-06 13:15
【抗流感概念持续走高 太龙药业等十余股涨停】抗流感概念午后涨势持续扩大，太龙药业、以岭药业午后双双涨停，另外罗欣药业、华北制药、亚太药业、金石亚药等十余只成分股涨停。
异动快报：亚太药业（002370）1月6日9点38分触及涨停板
证券之星 · 01-06 09:44
异动快报：亚太药业（002370）1月6日9点38分触及涨停板
亚太药业收盘下跌0.97%，最新市净率4.38
金融界 · 2024-12-31
亚太药业收盘下跌0.97%，最新市净率4.38
【亚药转债：回售申报期为2025年1月3日至2025年1月9日】浙江亚太药业股份有限公司公告，“亚药转债”的回售申报期为2025年1月3日至2025年1月9日。回售价格为101.512元/张（含息、税），投资者可在回售申报期内通过深圳证券交易所交易系统进行回售申报。
金融界 · 2024-12-30
【亚药转债：回售申报期为2025年1月3日至2025年1月9日】浙江亚太药业股份有限公司公告，“亚药转债”的回售申报期为2025年1月3日至2025年1月9日。回售价格为101.512元/张（含息、税），投资者可在回售申报期内通过深圳证券交易所交易系统进行回售申报。
亚太药业（002370）12月24日主力资金净卖出2079.64万元
证券之星 · 2024-12-25
亚太药业（002370）12月24日主力资金净卖出2079.64万元
亚太药业收盘下跌3.92%，最新市净率4.58
金融界 · 2024-12-24
亚太药业收盘下跌3.92%，最新市净率4.58
亚太药业（002370）12月19日主力资金净卖出1597.20万元
证券之星 · 2024-12-20
亚太药业（002370）12月19日主力资金净卖出1597.20万元
亚太药业（002370）12月13日主力资金净卖出4215.05万元
证券之星 · 2024-12-16
亚太药业（002370）12月13日主力资金净卖出4215.05万元
亚太药业(002370.SZ)：注射用头孢美唑钠药品补充申请获批准
智通财经 · 2024-12-13
亚太药业(002370.SZ)：注射用头孢美唑钠药品补充申请获批准
亚太药业（002370）12月9日主力资金净买入6895.34万元
证券之星 · 2024-12-10
亚太药业（002370）12月9日主力资金净买入6895.34万元
异动快报：亚太药业（002370）12月9日9点53分触及涨停板
证券之星 · 2024-12-09
异动快报：亚太药业（002370）12月9日9点53分触及涨停板
亚太药业最新公告：公司注射用泮托拉唑钠通过仿制药一致性评价
证券之星 · 2024-11-29
亚太药业最新公告：公司注射用泮托拉唑钠通过仿制药一致性评价
亚太药业：公司注射用泮托拉唑钠通过仿制药一致性评价
美港电讯 · 2024-11-29
亚太药业：公司注射用泮托拉唑钠通过仿制药一致性评价
亚太药业(002370.SZ)：注射用泮托拉唑钠通过一致性评价
智通财经 · 2024-11-29
亚太药业(002370.SZ)：注射用泮托拉唑钠通过一致性评价
亚太药业最新公告：收到盐酸地尔硫䓬片一致性评价受理通知书
证券之星 · 2024-11-28
亚太药业最新公告：收到盐酸地尔硫䓬片一致性评价受理通知书
亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价获受理
智通财经 · 2024-11-28
亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价获受理
图解亚太药业三季报：第三季度单季净利润同比增51.72%
证券之星 · 2024-10-31
图解亚太药业三季报：第三季度单季净利润同比增51.72%
异动快报：亚太药业（002370）10月9日14点55分触及跌停板
证券之星 · 2024-10-09
异动快报：亚太药业（002370）10月9日14点55分触及跌停板
亚太药业（002370）9月26日主力资金净卖出77.77万元
证券之星 · 2024-09-27
亚太药业（002370）9月26日主力资金净卖出77.77万元
加载更多
公司概况
公司名称：
浙江亚太药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-03-16
主营业务：
浙江亚太药业股份有限公司主要从事医药制造业务，包括化学制剂、化学原料药的研发、生产和销售。公司主要产品包括抗阿莫西林克拉维酸钾分散片、阿奇霉素分散片、注射用阿奇霉素、罗红霉素胶囊、注射用头孢唑肟钠等。罗红霉素胶囊、头孢氨苄胶囊、阿奇霉素分散片及注射用阿奇霉素为本公司的主导产品。
发行价格：
16.00
{"stockData":{"symbol":"002370","market":"SZ","secType":"STK","nameCN":"亚太药业","latestPrice":3.34,"timestamp":1736319810000,"preClose":3.2,"halted":0,"volume":92728097,"delay":0,"changeRate":0.0437,"floatShares":729000000,"shares":729000000,"eps":-0.0228,"marketStatus":"已收盘","change":0.14,"latestTime":"01-08 15:00:00","open":3.18,"high":3.52,"low":3.08,"amount":308000000,"amplitude":0.1375,"askPrice":3.35,"askSize":2034,"bidPrice":3.34,"bidSize":5856,"shortable":0,"etf":0,"ttmEps":-0.0228,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1736386200000},"marketStatusCode":5,"adr":0,"adjPreClose":3.2,"symbolType":"stock","openAndCloseTimeList":[[1736299800000,1736307000000],[1736312400000,1736319600000]],"highLimit":3.52,"lowLimit":2.88,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":728586186,"isCdr":false,"pbRate":4.7,"roa":"--","roe":"--","epsLYR":-0.02,"committee":-0.078232,"marketValue":2433000000,"turnoverRate":0.1273,"status":0,"floatMarketCap":2433000000},"requestUrl":"/m/hq/s/002370","defaultTab":"news","newsList":[{"id":"2501724659","title":"亚太药业最新公告：公司收到浙江省高级人民法院下发的《民事裁定书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2501724659","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501724659?lang=zh_cn&edition=full","pubTime":"2025-01-08 21:09","pubTimestamp":1736341775,"startTime":"0","endTime":"0","summary":"亚太药业公告，公司于近日收到浙江省高级人民法院下发的《民事裁定书》。浙商银行股份有限公司绍兴越城支行以股东损害债权人利益责任纠纷为由对公司及实际控制人陈尧根提起诉讼，请求公司对陈尧根的合计6656.30万元债务履行承担连带责任。浙江省高级人民法院裁定驳回浙商银行股份有限公司绍兴越城支行的再审申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010800038493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2501047474","title":"【抗流感概念持续走高 太龙药业等十余股涨停】抗流感概念午后涨势持续扩大，太龙药业、以岭药业午后双双涨停，另外罗欣药业、华北制药、亚太药业、金石亚药等十余只成分股涨停。","url":"https://stock-news.laohu8.com/highlight/detail?id=2501047474","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501047474?lang=zh_cn&edition=full","pubTime":"2025-01-06 13:15","pubTimestamp":1736140525,"startTime":"0","endTime":"0","summary":"抗流感概念午后涨势持续扩大，太龙药业、以岭药业午后双双涨停，另外罗欣药业、华北制药、亚太药业、金石亚药等十余只成分股涨停。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/06131547143355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0042","BK0077","BK0191","BK0188","300434","002603","002370","600812","BK0028","600222","BK0201","BK0001","08058","BK0046","BK0132","BK0239","BK0097","002793"],"gpt_icon":0},{"id":"2501794424","title":"异动快报：亚太药业（002370）1月6日9点38分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2501794424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501794424?lang=zh_cn&edition=full","pubTime":"2025-01-06 09:44","pubTimestamp":1736127866,"startTime":"0","endTime":"0","summary":"证券之星1月6日盘中消息，9点38分亚太药业触及涨停板。目前价格3.16，上涨10.1%。其所属行业化学制药目前上涨。领涨股为一品红。该股为创新药，化学原料药，新冠病毒防治概念热股，当日创新药概念上涨0.54%，化学原料药概念上涨0.45%，新冠病毒防治概念上涨0.33%。1月3日的资金流向数据方面，主力资金净流出600.83万元，占总成交额7.53%，游资资金净流入192.04万元，占总成交额2.41%，散户资金净流入408.8万元，占总成交额5.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010600005169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2495665105","title":"亚太药业收盘下跌0.97%，最新市净率4.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2495665105","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495665105?lang=zh_cn&edition=full","pubTime":"2024-12-31 16:50","pubTimestamp":1735635051,"startTime":"0","endTime":"0","summary":"12月31日，亚太药业今日收盘3.05元，下跌0.97%，最新市净率4.38。资金流向方面，12月31日，亚太药业主力资金净流出939.43万元，近5日总体呈流出状态，5日共流出2198.63万元。浙江亚太药业股份有限公司主要从事医药制造业务，包括化学制剂、化学原料药的研发、生产和销售。最新一期业绩显示，2024年三季报，公司实现营业收入3.07亿元，同比1.65%；净利润-3459530.47元，同比-374.48%，销售毛利率31.10%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/31165046988330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2495474385","title":"【亚药转债：回售申报期为2025年1月3日至2025年1月9日】浙江亚太药业股份有限公司公告，“亚药转债”的回售申报期为2025年1月3日至2025年1月9日。回售价格为101.512元/张（含息、税），投资者可在回售申报期内通过深圳证券交易所交易系统进行回售申报。","url":"https://stock-news.laohu8.com/highlight/detail?id=2495474385","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495474385?lang=zh_cn&edition=full","pubTime":"2024-12-30 21:48","pubTimestamp":1735566516,"startTime":"0","endTime":"0","summary":"浙江亚太药业股份有限公司公告，“亚药转债”的回售申报期为2025年1月3日至2025年1月9日。回售价格为101.512元/张（含息、税），投资者可在回售申报期内通过深圳证券交易所交易系统进行回售申报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2024/12/30214846963063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["399001","BK0239","BK0132","002370"],"gpt_icon":0},{"id":"2494645520","title":"亚太药业（002370）12月24日主力资金净卖出2079.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2494645520","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494645520?lang=zh_cn&edition=full","pubTime":"2024-12-25 09:21","pubTimestamp":1735089672,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月24日收盘，亚太药业报收于3.19元，下跌3.92%，换手率7.78%，成交量55.44万手，成交额1.77亿元。近5日资金流向一览见下表：亚太药业融资融券信息显示，融资方面，当日融资买入995.51万元，融资偿还1417.41万元，融资净偿还421.91万元。亚太药业主营业务：医药制造业务,包括化学制剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122500009186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2493777079","title":"亚太药业收盘下跌3.92%，最新市净率4.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2493777079","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493777079?lang=zh_cn&edition=full","pubTime":"2024-12-24 16:53","pubTimestamp":1735030394,"startTime":"0","endTime":"0","summary":"12月24日，亚太药业今日收盘3.19元，下跌3.92%，最新市净率4.58。截至2024年三季报，共有5家机构持仓亚太药业，其中其他3家、QFII2家，合计持股数13037.74万股，持股市值4.28亿元。浙江亚太药业股份有限公司主要从事医药制造业务，包括化学制剂、化学原料药的研发、生产和销售。最新一期业绩显示，2024年三季报，公司实现营业收入3.07亿元，同比1.65%；净利润-3459530.47元，同比-374.48%，销售毛利率31.10%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/24165346745186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK0132","002370"],"gpt_icon":0},{"id":"2492208437","title":"亚太药业（002370）12月19日主力资金净卖出1597.20万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492208437","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492208437?lang=zh_cn&edition=full","pubTime":"2024-12-20 09:22","pubTimestamp":1734657733,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月19日收盘，亚太药业报收于3.59元，下跌3.49%，换手率6.21%，成交量44.26万手，成交额1.6亿元。近5日资金流向一览见下表：亚太药业融资融券信息显示，融资方面，当日融资买入1019.28万元，融资偿还1153.92万元，融资净偿还134.64万元。亚太药业主营业务：医药制造业务,包括化学制剂的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122000007787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2491850736","title":"亚太药业（002370）12月13日主力资金净卖出4215.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491850736","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491850736?lang=zh_cn&edition=full","pubTime":"2024-12-16 09:32","pubTimestamp":1734312766,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月13日收盘，亚太药业报收于3.95元，下跌4.36%，换手率12.18%，成交量86.85万手，成交额3.47亿元。近5日资金流向一览见下表：亚太药业融资融券信息显示，融资方面，当日融资买入2008.91万元，融资偿还2149.89万元，融资净偿还140.98万元。亚太药业主营业务：医药制造业务,包括化学制剂的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121600002490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2491458743","title":"亚太药业(002370.SZ)：注射用头孢美唑钠药品补充申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2491458743","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491458743?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:34","pubTimestamp":1734078844,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的关于注射用头孢美唑钠的《药品补充申请批准通知书》。本次获得注射用头孢美唑钠药品补充申请批准通知书，并在原1.0g规格基础上增加2.0g、0.5g规格，将进一步丰富公司的产品品类，为该品种的市场推广提供更多选择，有利于提升该药品的市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0132","002370"],"gpt_icon":0},{"id":"2490036808","title":"亚太药业（002370）12月9日主力资金净买入6895.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490036808","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490036808?lang=zh_cn&edition=full","pubTime":"2024-12-10 09:10","pubTimestamp":1733793049,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月9日收盘，亚太药业报收于4.14元，上涨10.11%，涨停，换手率20.65%，成交量129.09万手，成交额5.23亿元。近5日资金流向一览见下表：亚太药业融资融券信息显示，融资方面，当日融资买入3486.32万元，融资偿还3568.91万元，融资净偿还82.59万元。亚太药业主营业务：医药制造业务,包括化学制剂的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121000009857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2490979889","title":"异动快报：亚太药业（002370）12月9日9点53分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2490979889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490979889?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:55","pubTimestamp":1733709324,"startTime":"0","endTime":"0","summary":"证券之星12月9日盘中消息，9点53分亚太药业（002370）触及涨停板。目前价格4.14，上涨10.11%。其所属行业化学制药目前上涨。领涨股为河化股份。该股为创新药，工业大麻，医药概念热股，当日创新药概念上涨1.44%，工业大麻概念上涨1.26%，医药概念上涨1.23%。12月6日的资金流向数据方面，主力资金净流入1483.58万元，占总成交额9.76%，游资资金净流出743.62万元，占总成交额4.89%，散户资金净流出739.96万元，占总成交额4.87%。近5日资金流向一览见下表：亚太药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120900004595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2487822285","title":"亚太药业最新公告：公司注射用泮托拉唑钠通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2487822285","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487822285?lang=zh_cn&edition=full","pubTime":"2024-11-29 16:19","pubTimestamp":1732868368,"startTime":"0","endTime":"0","summary":"亚太药业公告，近日收到国家药品监督管理局核准签发的关于注射用泮托拉唑钠的《药品补充申请批准通知书》，公司注射用泮托拉唑钠（80mg、40mg、60mg）通过仿制药质量和疗效一致性评价。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112900023666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2487845245","title":"亚太药业：公司注射用泮托拉唑钠通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2487845245","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487845245?lang=zh_cn&edition=full","pubTime":"2024-11-29 15:57","pubTimestamp":1732867036,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2487584368","title":"亚太药业(002370.SZ)：注射用泮托拉唑钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2487584368","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487584368?lang=zh_cn&edition=full","pubTime":"2024-11-29 15:53","pubTimestamp":1732866816,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)公告，公司于近日收到国家药品监督管理局核准签发的关于注射用泮托拉唑钠的《药品补充申请批准通知书》，公司注射用泮托拉唑钠通过仿制药质量和疗效一致性评价。注射用泮托拉唑钠适用于十二指肠溃疡、胃溃疡、中重度反流性食管炎、急性胃黏膜病变、复合性胃溃疡等引起的急性上消化道出血。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2486362069","title":"亚太药业最新公告：收到盐酸地尔硫䓬片一致性评价受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486362069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486362069?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:43","pubTimestamp":1732783380,"startTime":"0","endTime":"0","summary":"亚太药业公告，公司近日收到国家药品监督管理局下发的关于盐酸地尔硫䓬片一致性评价的受理通知书。该药品适用于心绞痛和轻、中度高血压的治疗。公司将积极推进后续相关工作，如顺利通过一致性评价将增加其市场竞争力。药品一致性评价审评工作流程有一定的时间周期，存在不确定性因素。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800025750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2486636469","title":"亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486636469","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486636469?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:17","pubTimestamp":1732781857,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)公告，公司近日收到国家药品监督管理局下发的关于盐酸地尔硫䓬片一致性评价的受理通知书。盐酸地尔硫䓬片适用于心绞痛和轻、中度高血压的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2479861737","title":"图解亚太药业三季报：第三季度单季净利润同比增51.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479861737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479861737?lang=zh_cn&edition=full","pubTime":"2024-10-31 01:18","pubTimestamp":1730308707,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业2024年三季报显示，公司主营收入3.07亿元，同比上升1.65%；归母净利润-345.95万元，同比下降374.48%；扣非净利润-2259.21万元，同比上升61.16%；其中2024年第三季度，公司单季度主营收入8490.25万元，同比上升5.18%；单季度归母净利润-893.47万元，同比上升51.72%；单季度扣非净利润-1476.54万元，同比上升39.35%；负债率53.95%，投资收益1585.38万元，财务费用1641.1万元，毛利率31.1%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100002308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2474296741","title":"异动快报：亚太药业（002370）10月9日14点55分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2474296741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474296741?lang=zh_cn&edition=full","pubTime":"2024-10-09 15:02","pubTimestamp":1728457374,"startTime":"0","endTime":"0","summary":"证券之星10月9日盘中消息，14点55分亚太药业（002370）触及跌停板。目前价格3.13，下跌10.06%。其所属行业化学制药目前下跌。领涨股为双成药业。该股为幽门螺杆菌概念，工业大麻，创新药概念热股。10月9日的资金流向数据方面，主力资金净流出1604.33万元，占总成交额9.71%，游资资金净流出9.62万元，占总成交额0.06%，散户资金净流入1613.95万元，占总成交额9.77%。近5日资金流向一览见下表：亚太药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100900018272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2470194217","title":"亚太药业（002370）9月26日主力资金净卖出77.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470194217","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470194217?lang=zh_cn&edition=full","pubTime":"2024-09-27 09:22","pubTimestamp":1727400140,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年9月26日收盘，亚太药业报收于2.9元，上涨1.05%，换手率6.59%，成交量40.14万手，成交额1.15亿元。近5日资金流向一览见下表：亚太药业融资融券信息显示，融资方面，当日融资买入440.98万元，融资偿还484.65万元，融资净偿还43.67万元。亚太药业主营业务：医药制造业务,包括化学制剂的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092700006615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002370","BK0132"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-03-16","address":"浙江省绍兴市柯桥区群贤路2003号1501室","stockEarnings":[{"period":"1week","weight":0.0951},{"period":"1month","weight":-0.1932},{"period":"3month","weight":0.0637},{"period":"6month","weight":0.336},{"period":"1year","weight":-0.201},{"period":"ytd","weight":0.0951}],"companyName":"浙江亚太药业股份有限公司","boardCode":"AI0027","perCapita":"11338股","boardName":"医药制造业","registeredCapital":"72858万元","compareEarnings":[{"period":"1week","weight":-0.0363},{"period":"1month","weight":-0.0507},{"period":"3month","weight":-0.0217},{"period":"6month","weight":0.0871},{"period":"1year","weight":0.1164},{"period":"ytd","weight":-0.0363}],"survey":" 浙江亚太药业股份有限公司主要从事医药制造业务，包括化学制剂、化学原料药的研发、生产和销售。公司主要产品包括抗阿莫西林克拉维酸钾分散片、阿奇霉素分散片、注射用阿奇霉素、罗红霉素胶囊、注射用头孢唑肟钠等。罗红霉素胶囊、头孢氨苄胶囊、阿奇霉素分散片及注射用阿奇霉素为本公司的主导产品。","serverTime":1736372347675,"listedPrice":16,"stockholders":"64255人(较上一季度增加8.73%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚太药业,002370,亚太药业股票,亚太药业股票老虎,亚太药业股票老虎国际,亚太药业行情,亚太药业股票行情,亚太药业股价,亚太药业股市,亚太药业股票价格,亚太药业股票交易,亚太药业股票购买,亚太药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}